Novo Nordisk A/S found using ticker (NVO) have now 5 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 173.99 and 119.99 calculating the average target price we see 152.06. Now with the previous closing price of 142.86 this would indicate that there is a potential upside of 6.4%. The 50 day moving average now sits at 138.16 and the 200 moving average now moves to 117.18. The market cap for the company is $323,268m. Find out more information at: https://www.novonordisk.com
The potential market cap would be $344,086m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
